212 related articles for article (PubMed ID: 29858866)
21. Recommendations on the effect of antidiabetic drugs in bone.
Rozas-Moreno P; Reyes-García R; Jódar-Gimeno E; Varsavsky M; Luque-Fernández I; Cortés-Berdonces M; Muñoz-Torres M;
Endocrinol Diabetes Nutr; 2017 Mar; 64 Suppl 1():1-6. PubMed ID: 28440761
[TBL] [Abstract][Full Text] [Related]
22. The backbone of oral glucose-lowering therapy: time for a paradigm shift?
Seufert J
Fundam Clin Pharmacol; 2009 Dec; 23(6):651-67. PubMed ID: 19469803
[TBL] [Abstract][Full Text] [Related]
23. Cost Effectiveness of Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors, Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists, and Dipeptidyl Peptidase-4 (DPP-4) Inhibitors: A Systematic Review.
Hong D; Si L; Jiang M; Shao H; Ming WK; Zhao Y; Li Y; Shi L
Pharmacoeconomics; 2019 Jun; 37(6):777-818. PubMed ID: 30854589
[TBL] [Abstract][Full Text] [Related]
24. Cardiovascular safety of glucose-lowering agents as add-on medication to metformin treatment in type 2 diabetes: report from the Swedish National Diabetes Register.
Ekström N; Svensson AM; Miftaraj M; Franzén S; Zethelius B; Eliasson B; Gudbjörnsdottir S
Diabetes Obes Metab; 2016 Oct; 18(10):990-8. PubMed ID: 27282621
[TBL] [Abstract][Full Text] [Related]
25. Cardiovascular safety of therapies for type 2 diabetes.
Gupta P; White WB
Expert Opin Drug Saf; 2017 Jan; 16(1):13-25. PubMed ID: 27652617
[TBL] [Abstract][Full Text] [Related]
26. Dementia Diagnosis Is Associated with Changes in Antidiabetic Drug Prescription: An Open-Cohort Study of ∼130,000 Swedish Subjects over 14 Years.
Secnik J; Xu H; Schwertner E; Hammar N; Alvarsson M; Winblad B; Eriksdotter M; Garcia-Ptacek S; Religa D
J Alzheimers Dis; 2020; 76(4):1581-1594. PubMed ID: 32741836
[TBL] [Abstract][Full Text] [Related]
27. Pharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus.
Tahrani AA; Barnett AH; Bailey CJ
Nat Rev Endocrinol; 2016 Oct; 12(10):566-92. PubMed ID: 27339889
[TBL] [Abstract][Full Text] [Related]
28. Diabetes, antidiabetic medications and risk of dementia: A systematic umbrella review and meta-analysis.
Kuate Defo A; Bakula V; Pisaturo A; Labos C; Wing SS; Daskalopoulou SS
Diabetes Obes Metab; 2024 Feb; 26(2):441-462. PubMed ID: 37869901
[TBL] [Abstract][Full Text] [Related]
29. The pharmacologic basis for clinical differences among GLP-1 receptor agonists and DPP-4 inhibitors.
Morales J
Postgrad Med; 2011 Nov; 123(6):189-201. PubMed ID: 22104467
[TBL] [Abstract][Full Text] [Related]
30. Cardiovascular Safety and Benefits of Noninsulin Antihyperglycemic Drugs for the Treatment of Type 2 Diabetes Mellitus-Part 1.
Yandrapalli S; Jolly G; Horblitt A; Pemmasani G; Sanaani A; Aronow WS; Frishman WH
Cardiol Rev; 2020; 28(4):177-189. PubMed ID: 32282393
[TBL] [Abstract][Full Text] [Related]
31. What to add in with metformin in type 2 diabetes?
Petrie JR; Adler A; Vella S
QJM; 2011 Mar; 104(3):185-92. PubMed ID: 21156663
[TBL] [Abstract][Full Text] [Related]
32. Overview of Data Concerning the Safe Use of Antihyperglycemic Medications in Type 2 Diabetes Mellitus and Chronic Kidney Disease.
Roussel R; Lorraine J; Rodriguez A; Salaun-Martin C
Adv Ther; 2015 Nov; 32(11):1029-64. PubMed ID: 26581749
[TBL] [Abstract][Full Text] [Related]
33. Preadmission use of antidiabetic medications and mortality among patients with COVID-19 having type 2 diabetes: A meta-analysis.
Nguyen NN; Ho DS; Nguyen HS; Ho DKN; Li HY; Lin CY; Chiu HY; Chen YC
Metabolism; 2022 Jun; 131():155196. PubMed ID: 35367460
[TBL] [Abstract][Full Text] [Related]
34. Comparative efficacy and safety of antidiabetic drug regimens added to stable and inadequate metformin and thiazolidinedione therapy in type 2 diabetes.
Saulsberry WJ; Coleman CI; Mearns ES; Zaccaro E; Doleh Y; Sobieraj DM
Int J Clin Pract; 2015 Nov; 69(11):1221-35. PubMed ID: 26215321
[TBL] [Abstract][Full Text] [Related]
35. A review on cardiovascular effects of newer hypoglycaemic medications.
Cutshall BT; Twilla JD; Olinger AS; Oliphant CS
Ann Med; 2017 Nov; 49(7):603-612. PubMed ID: 28540743
[TBL] [Abstract][Full Text] [Related]
36. Comparative risk of major cardiovascular events associated with second-line antidiabetic treatments: a retrospective cohort study using UK primary care data linked to hospitalization and mortality records.
Zghebi SS; Steinke DT; Rutter MK; Emsley RA; Ashcroft DM
Diabetes Obes Metab; 2016 Sep; 18(9):916-24. PubMed ID: 27177784
[TBL] [Abstract][Full Text] [Related]
37. Evaluating second-line treatment options for type 2 diabetes: focus on secondary effects of GLP-1 agonists and DPP-4 inhibitors.
Boland CL; Degeeter M; Nuzum DS; Tzefos M
Ann Pharmacother; 2013 Apr; 47(4):490-505. PubMed ID: 23548652
[TBL] [Abstract][Full Text] [Related]
38. Cardiovascular disease and oral agent glucose-lowering therapies in the management of type 2 diabetes.
Home P
Diabetes Technol Ther; 2012 Jun; 14 Suppl 1():S33-42. PubMed ID: 22650223
[TBL] [Abstract][Full Text] [Related]
39. Cardiovascular safety of combination therapies with incretin-based drugs and metformin compared with a combination of metformin and sulphonylurea in type 2 diabetes mellitus--a retrospective nationwide study.
Mogensen UM; Andersson C; Fosbøl EL; Schramm TK; Vaag A; Scheller NM; Torp-Pedersen C; Gislason G; Køber L
Diabetes Obes Metab; 2014 Oct; 16(10):1001-8. PubMed ID: 24827939
[TBL] [Abstract][Full Text] [Related]
40. Efficacy and safety of dipeptidyl peptidase-4 inhibitors in combination with metformin.
Fass AD; Gershman JA
Adv Ther; 2013 Apr; 30(4):337-53. PubMed ID: 23605247
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
